Concentra Group Holdings Parent vs U S Physical Therapy
CON and USPH side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CON and USPH compare
Concentra Group Holdings Parent is the larger company, worth 3.7 times as much as U S Physical Therapy ($5.5B against $1.5B).
Concentra Group Holdings Parent grew revenue faster over the last twelve months (11.8% versus 10.4% for U S Physical Therapy).
Concentra Group Holdings Parent keeps more of each dollar of sales as profit, with a net margin of 9.3% compared with 3.6% at U S Physical Therapy.
Both pay dividends: Concentra Group Holdings Parent yields 0.58% and U S Physical Therapy 1.8%.
Concentra Group Holdings Parent scores higher on the StockData Score (12 against 9 for U S Physical Therapy), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CON | USPH |
|---|---|---|
| Size and price | ||
| Market cap | $5.5B | $1.5B |
| Share price | $43.45 | $100.10 |
| Change, 1 year | 126% | 36.6% |
| Change, 5 years | – | 9.9% |
| Beta (5Y) | 0.50 | 0.72 |
| Employees | 13K | 7,294 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 4 (better) | 3 |
| Health score | 2 | 2 |
| Dividend score | 3 (better) | 1 |
| Valuation | ||
| P/E | 25.9× | – |
| P/S | 2.4× | 1.8× (better) |
| P/B | 10.9× | 3.5× (better) |
| EV/EBITDA | 14.7× (better) | 17.3× |
| P/FCF | 21.5× (better) | 21.6× |
| FCF yield | 4.6% (better) | 4.6% |
| Fair value | $36.45 | $82.03 |
| Margin of safety | −19.2% (better) | −22.0% |
| Growth | ||
| Revenue growth (TTM) | 11.8% (better) | 10.4% |
| Revenue growth, 5Y average | – | 13.0% |
| Net income growth (TTM) | 41.2% (better) | −32.5% |
| EPS growth (TTM) | 40.0% | – |
| EPS growth, 5Y average | – | −10.6% |
| Profitability | ||
| Gross margin | 29.9% (better) | 18.8% |
| Operating margin | 16.9% (better) | 9.1% |
| Net margin | 9.3% (better) | 3.6% |
| FCF margin | 11.0% (better) | 8.2% |
| Return on equity | 48.5% (better) | 6.5% |
| Return on invested capital | 15.6% (better) | 9.1% |
| Financial health | ||
| Debt / equity | 3.00 | 0.57 (better) |
| Net debt / EBITDA | 3.02 | 2.11 (better) |
| Current ratio | 1.30 | 1.42 (better) |
| Altman Z-score | 2.74 | 2.85 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.58% | 1.8% (better) |
| Payout ratio | 14.8% | – |
| Years of dividend growth | 1 | 5 (better) |
| Dividend growth, 5Y average | – | 41.3% |
| Buyback yield | 1.5% | – |
| Shareholder yield | 2.1% (better) | 1.8% |
| Ownership | ||
| Held by institutions | 88.2% | 109% |
| Held by insiders | 11.3% | 2.6% |
| Insider net buying, 12 months | −$14.6M | −$397K (better) |
| Short interest, % of float | 2.0% | 7.8% |
Go deeper
- CON stock overview
- CON income statement
- CON valuation and score
- USPH stock overview
- USPH income statement
- USPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.